American Journal of Respiratory and Critical Care Medicine · 2017 · 42 citations · 26 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyPulmonologyRespiratory PharmacotherapyBronchodilator TherapyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyCombination Inhaler TherapyRespiratory DiseaseRespiratory MedicineChronic Obstructive Pulmonary Disease Exacerbation TreatmentCombination TherapyInhaled Corticosteroid CombinationsLaba CombinationsLong-acting Beta AgonistsLong-acting Beta2-agonistsLong-acting Bronchodilator TherapyMulticenter Trials
RATIONALE: -agonists (LABA) at the onset of upper respiratory tract infection (URTI) symptoms in chronic obstructive pulmonary disease (COPD) is unknown. OBJECTIVES: To evaluate whether intensified combination therapy with ICS/LABA, at the onset of URTI symptoms, decreases the incidence of COPD exacerbation occurring within 21 days of the URTI. METHODS: A total of 450 patients with stable, moderate to very severe COPD, were included in this investigator-initiated and -driven, double-blind, randomized, placebo-controlled study. At inclusion, patients were assigned to open-labeled low-maintenance dose ICS/LABA. Each patient was randomized either to intensified-dose ICS/LABA or placebo and instructed to start using this medication only in case of a URTI, at the onset of symptoms, twice daily, for 10 days. MEASUREMENTS AND MAIN RESULTS: The incidence of any exacerbation following a URTI was not significantly decreased in the ICS/LABA group, as compared with placebo (14.6% vs. 16.2%; hazard ratio, 0.77; 95% confidence interval, 0.46-1.33; P = 0.321) but the risk of severe exacerbation was decreased by 72% (hazard ratio, 0.28; 95% confidence interval, 0.11-0.74%; P = 0.010). In the stratified analysis, effect size was modified by disease severity, fractional exhaled nitric oxide, and the body mass index-airflow obstruction-dyspnea, and exercise score. Compared with the stable period, evidence of at least one virus was significantly more common at URTI, 10 days after URTI, and at exacerbation. CONCLUSIONS: Intensified combination therapy with ICS/LABA for 10 days at URTI onset did not decrease the incidence of any COPD exacerbation but prevented severe exacerbation. Patients with more severe disease had a significant risk reduction for any exacerbation. Clinical trial registered with www.isrctn.com (ISRCTN45572998).
26
The St George's Respiratory Questionnaire
Paul Jones, Frances Quirk, Chloë M. Baveystock · Respiratory Medicine · 1991 · 2.7K citations · Full text
Raed A. Dweik, Peter B. Boggs, Serpil C. Erzurum et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 2.5K citations